查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1939533

全球氟化藥物市場（按藥物類型、治療領域、給藥途徑、研發階段、化合物類別、最終用戶和分銷管道分類），2026-2032年預測

Fluorinated Drugs Market by Drug Type, Therapeutic Area, Route Of Administration, Development Stage, Compound Class, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年氟化藥物市值為 3.8283 億美元，預計到 2026 年將成長至 4.073 億美元，年複合成長率為 6.38%，到 2032 年將達到 5.9052 億美元。

關鍵市場統計數據
基準年 2025 3.8283億美元
預計年份：2026年 4.073億美元
預測年份 2032 5.9052億美元
複合年成長率 (%) 6.38%

透過科學證據、臨床差異化以及對開發平臺的策略意義，探索氟化藥物的興起。

氟的引進已成為現代藥物研發中至關重要的策略槓桿。本文將簡要介紹氟元素為何值得經營團隊和科學家特別關注。氟元素因其影響代謝穩定性、親油性和受體相互作用的能力而備受重視，如今，它已成為藥物化學創新和實際藥物開發考量的關鍵。隨著專案從標靶檢驗推進到臨床開發，決策者必須權衡科學價值與生產複雜性、監管要求和供應鏈限制之間的關係。

變革性的監管變化正在加速氟化學技術的應用，並改變臨床試驗設計、生產製造和供應鏈。

在含氟藥物領域，科學、技術和監管因素正相互交融，帶來變革性變化，這將對藥物研發計畫的發展軌跡產生重大影響。合成方法和氟化化學的進步拓展了藥物化學家的工具箱，使得氟原子的定位更加精準，並促進了以往難以實現的後期修飾。同時，製程化學和流動技術的改進也開始解決以往放大生產所面臨的挑戰，使得中試宣傳活動能夠獲得更高的產率和更純淨的雜質譜。

評估美國計劃於2025年實施的關稅調整對含氟藥品採購、生產連續性和全球籌資策略的累積影響

美國即將於2025年調整的關稅政策，將為氟化藥物研發企業在採購、生產連續性和全球採購網路等方面帶來複雜的壓力。關稅變化將影響原料和某些中間體的成本，尤其會影響氟化製程中的關鍵化合物，例如特殊試劑和催化劑系統。因此，採購團隊正在重新審視供應商結構，並評估近岸外包方案，以確保關鍵原料的穩定供應。

細分分析透過藥物類型、治療領域、給藥途徑、研發階段、化合物類別和通路來識別促進因素。

了解市場區隔對於將宏觀趨勢轉化為可執行策略至關重要，因為不同的市場維度揭示了研發、生產和商業化過程中不同的關鍵挑戰。按藥物類型分類，該細分市場涵蓋生物製藥、胜肽和小分子藥物。在生物製藥中，單株抗體、核酸和重組蛋白各有其獨特的考量因素，氟化作用可應用於偶聯物、示蹤劑化學和穩定性調節輔料，而非聚合物本身。小分子藥物和胜肽類藥物仍然是氟化學最直接的受益者，因為取代模式對代謝穩定性和標靶選擇性有顯著影響。

區域趨勢和競爭格局正在影響關鍵區域的氟化藥物研發、監管互動、製造地和市場進入等考量。

區域趨勢對研發時間表、生產決策和監管路徑有顯著影響。相關人員在規劃含氟藥物項目時必須考慮區域性因素。在美洲，對先進生產設施的投資以及強大的合約研發生產機構 (CDMO) 系統支援快速規模化生產，而監管機構則高度重視雜質表徵和完善的品質系統。這種組合促使申辦方將製程驗證和分析開發與臨床里程碑緊密結合，以避免延誤並確保市場進入。

主要企業、夥伴關係和創新路徑概況，這些都定義了氟化藥物研發領域的競爭定位和研發重點。

氟化藥物生態系統中的主要企業透過平台能力、策略夥伴關係和有針對性的先導化合物投資相結合的方式，建立了競爭優勢。那些投資先進氟化化學、氟化化合物庫高通量篩檢或專有製程增強技術的企業，能夠更好地加速先導化合物最佳化，並縮短從候選藥物篩選到新藥臨床試驗申請（IND）準備的時間。處於發現階段的企業與特種化學品供應商之間的合作，在彌補能力差距和降低氟化中間體規模化生產風險方面也發揮著至關重要的作用。

針對氟化藥物研發投資、供應鏈韌性和監管應對，提出清晰、優先且可操作的建議

產業領導者應採取一系列優先且切實可行的舉措，以充分利用氟化技術的科學優勢，同時管控其營運和監管風險。首先，他們應系統性地建立藥物發現化學、製程開發和監管事務之間的緊密合作，確保藥物發現過程中所做的氟化決策能夠得到下游生產可行性和雜質控制的支持。早期跨部門合作可以減少返工，並加速從候選藥物篩選到臨床批量生產的過渡。

透明的調查方法：清楚闡述資料來源、檢驗方法、專家諮詢以及用於評估藥物趨勢的分析架構。

本分析的研究途徑結合了對同行評審文獻的系統性回顧、專家諮詢以及監管指南的綜合分析，以得出可重複且有效的結論。資料收集首先透過有針對性的文獻檢索，捕捉氟化化學、製程強化和臨床應用的最新進展，隨後對已發表的與鹵代化合物相關的監管文件和指南進行主題評估。在此基礎上，我們與藥物化學、製程開發、法規事務和供應鏈管理領域的專家進行了結構化訪談，以檢驗假設並識別在開發和規模化生產過程中遇到的實際挑戰。

最後，我們總結了參與氟化藥物創新和市場准入的相關人員所面臨的策略意義、新興風險和機會。

總之，含氟藥物代表著一個戰略前沿領域，化學創新可以顯著改善其臨床療效，但同時也帶來了巨大的營運和監管複雜性。合成可行性、雜質控制、供應鏈韌性和臨床差異化之間的相互作用，將決定氟化作用的理論優勢能否轉化為實際的治療效果和商業性成功。因此，相關人員必須採取整合藥物發現科學、製程開發、監管規劃和商業性誠信的策略。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類型分類的含氟藥物市場

  • 生物製藥
    • 單株抗體
    • 核酸
    • 重組蛋白
  • 胜肽
  • 低分子化合物

9. 依治療領域分類的含氟藥物市場

  • 自體免疫疾病
  • 循環系統
    • 動脈粥狀硬化
    • 心臟衰竭
    • 高血壓
  • 中樞神經系統
  • 腫瘤學
    • 血液學
    • 固態腫瘤
  • 呼吸系統
    • 氣喘
    • 慢性阻塞性肺病

第10章 依給藥途徑分類的含氟藥物市場

  • 吸入
  • 注射
  • 口服
  • 外用
  • 經皮

第11章 含氟藥物市場依發展階段分類

  • 已通過核准的
  • I期試驗
  • 第二階段
  • III期臨床試驗
  • 臨床前階段

12. 依化合物類別的含氟藥物市場

  • 氟化脂肪族化合物
  • 氟化胺基酸
  • 氟化雜環化合物
  • 氟化芳香化合物

第13章 依最終用戶分類的含氟藥物市場

  • 診所
  • 居家醫療
  • 醫院
  • 零售藥房

第14章 含氟藥物市場依通路分類

  • 直銷
  • 批發商
  • 電子商務

第15章 各地區含氟藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 氟化藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國氟化藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國含氟藥物市場

第19章：中國的含氟藥物市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Cipla Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GSK plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-9A6A6F297811

The Fluorinated Drugs Market was valued at USD 382.83 million in 2025 and is projected to grow to USD 407.30 million in 2026, with a CAGR of 6.38%, reaching USD 590.52 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 382.83 million
Estimated Year [2026] USD 407.30 million
Forecast Year [2032] USD 590.52 million
CAGR (%) 6.38%

Framing the emergence of fluorinated therapeutics through scientific rationale, clinical differentiation, and strategic implications for development pipelines

Fluorine incorporation has become a defining strategic lever in modern drug discovery, and a concise introduction helps frame why this chemical element warrants particular attention from executives and scientists alike. Historically valued for its ability to influence metabolic stability, lipophilicity, and receptor interactions, fluorine now sits at the intersection of medicinal chemistry innovation and pragmatic drug development considerations. As programs progress from target validation to clinical development, decision-makers must reconcile the scientific advantages with manufacturing complexity, regulatory expectations, and supply chain constraints.

In the current landscape, fluorinated drugs span a broad therapeutic and technological spectrum, and understanding the underlying rationale for fluorination is the first step in parsing development choices. The introduction establishes a vantage point for assessing how fluorine-modified molecules can alter pharmacokinetics, improve oral bioavailability, and enable differentiated clinical profiles. Moreover, it situates these properties within the broader commercial context, where time-to-patient, scalability of synthesis, and strategic IP positioning are increasingly central to program success.

Consequently, this section sets out the critical themes that recur throughout the report: the scientific benefits of fluorination, the operational and regulatory trade-offs in synthesis and manufacturing, and the strategic decisions companies must make to convert molecular advantages into clinical and commercial outcomes. By orienting readers to these focal areas, the introduction prepares program leaders to interpret downstream analysis with an eye toward portfolio prioritization and practical implementation.

Transformative regulatory shifts accelerating fluorine chemistry adoption and altering clinical trial design, manufacturing, and supply chains

The landscape for fluorinated drugs is experiencing transformative shifts propelled by converging scientific, technological, and regulatory forces that materially influence program trajectories. Advances in synthetic methods and fluorination chemistry have expanded the toolkit available to medicinal chemists, enabling more precise placement of fluorine atoms and facilitating late-stage modifications that were previously impractical. At the same time, improvements in process chemistry and flow techniques have begun to address historical scale-up challenges, enabling pilot manufacturing campaigns with higher yields and cleaner impurity profiles.

Regulatory expectations are evolving in parallel. Agencies are increasingly focused on impurity characterization and control strategies for halogenated compounds, prompting sponsors to incorporate robust analytical packages earlier in development. This regulatory attention has, in turn, encouraged closer collaboration between discovery teams and process development groups, with an emphasis on minimizing risky synthetic steps and designing manufacturing pathways that can withstand tighter scrutiny.

Equally important are shifts in clinical strategy. As biomarkers and precision-medicine approaches mature, fluorinated molecules that deliver superior target engagement or improved central nervous system penetration are being repositioned for indications that prioritize differentiated safety and efficacy profiles. These clinical opportunities are supported by broader payer and provider interest in therapies that reduce administration burden or improve durability of response.

Finally, the supply chain and commercial models are adapting. Companies are reassessing supplier relationships, investing in redundant sourcing for critical fluorinated intermediates, and exploring regional manufacturing footprints to mitigate geopolitical and tariff-driven risks. Taken together, these shifts create a more dynamic environment in which scientific promise intersects with operational realities, necessitating integrated strategies that span discovery, development, and commercialization.

Assessing the cumulative consequences of anticipated United States tariff changes in 2025 on procurement, production continuity, and global sourcing strategies for fluorinated drugs

The approaching tariff adjustments in the United States for 2025 introduce a complex set of pressures across procurement, manufacturing continuity, and global sourcing networks that companies developing fluorinated drugs must anticipate. Tariff changes alter the cost calculus for raw materials and select intermediates, and in many cases they affect compounds that are critical to fluorination workflows, including specialized reagents and catalytic systems. Consequently, procurement teams are recalibrating supplier mixes and evaluating nearshoring options to preserve predictable access to key inputs.

Production continuity faces particular vulnerability when single-source suppliers dominate essential fluorinated intermediates. Under tariff pressure, previously economical suppliers may become costlier or less reliable, prompting manufacturers to diversify vendor bases and to accelerate qualification of secondary suppliers. In turn, this increases the need for rigorous quality and regulatory compliance checks, since alternative suppliers may operate under different process controls or impurity profiles. To preserve batch consistency and to prevent regulatory setbacks, companies are prioritizing process validation and impurity mapping as part of continuity planning.

From a global sourcing perspective, tariff dynamics are reshaping the trade-offs between cost and resilience. Some sponsors are exploring regionalized supply chains that reduce exposure to cross-border tariff volatility, while others are negotiating longer-term contracts or leveraging toll manufacturing relationships to lock in terms. These strategic choices carry operational consequences: shifting production closer to end markets can shorten lead times and reduce tariff impact, but it may require capital investment and a re-evaluation of existing partnerships.

In light of these trends, industry players must approach tariff-induced changes as an opportunity to strengthen procurement governance, enhance supplier diversification, and embed tariff sensitivity into clinical and commercial planning. Doing so reduces exposure to sudden cost shifts and supports uninterrupted development and patient supply.

Segmentation intelligence that clarifies drivers across drug type, therapeutic area, administration routes, development stages, compound classes and channels

Understanding segmentation is essential to translating broad trends into executable strategies, and distinct dimensions of the market reveal different imperatives for R&D, manufacturing, and commercialization. By drug type, the landscape encompasses biologics, peptides, and small molecules; within biologics, monoclonal antibodies, nucleic acids, and recombinant proteins each present unique considerations where fluorination may be used in conjugates, tracer chemistry, or stability-modulating excipients rather than in the macromolecule itself. Small molecules and peptides remain the most direct beneficiaries of fluorine chemistry, where substitution patterns can meaningfully influence metabolic stability and target selectivity.

Therapeutic area segmentation further refines strategic priorities. Across autoimmune, cardiovascular, central nervous system, oncology, and respiratory indications, fluorinated compounds play differing roles. Cardiovascular programs must contend with subsegments such as atherosclerosis, heart failure, and hypertension where the therapeutic window and long-term safety are paramount. Oncology efforts split between hematological and solid tumor strategies, each with distinct biomarker, delivery, and combination-therapy implications. Respiratory indications including asthma and chronic obstructive pulmonary disease require attention to inhalation performance and local tolerability, while central nervous system and autoimmune programs emphasize blood-brain-barrier penetration and immune modulation respectively.

Route of administration shapes formulation and development pathways; inhalation, injectable, oral, topical, and transdermal approaches demand divergent formulation science and regulatory testing. End users such as clinics, home care settings, hospitals, and retail pharmacies drive downstream considerations in packaging, stability, and patient adherence. Development stage segmentation-approved, phase I, phase II, phase III, and preclinical-reveals where cost, risk tolerance, and regulatory engagement differ, influencing how much resource is allocated to process robustness and impurity control.

Compound class distinctions among fluorinated aliphatics, fluorinated amino acids, fluorinated heterocycles, and fluoroarenes correlate with synthetic tractability and impurity risk profiles, while distribution channel segmentation-direct sales, distributors, and e-commerce-affects commercialization strategies and logistics planning. Synthesizing these segmentation lenses enables sponsors to prioritize investments, tailor regulatory strategies, and design supply chains consistent with therapeutic and formulation demands.

Regional dynamics and competitive nuances shaping fluorinated drug development, regulatory engagement, manufacturing footprints, and market access considerations across major geographies

Regional dynamics exert a powerful influence on development timelines, manufacturing decisions, and regulatory pathways, and stakeholders must consider geographically specific factors when planning fluorinated drug programs. In the Americas, investment in advanced manufacturing and a strong base of contract development and manufacturing organizations supports rapid scale-up, while regulatory agencies emphasize impurity characterization and robust quality systems. This combination encourages sponsors to align process validation and analytical development closely with clinical milestones to avoid delays and to ensure market access.

Europe, the Middle East & Africa present a heterogeneous environment where regulatory frameworks can vary significantly between jurisdictions. Sponsors must navigate centralized and national approval pathways, engage proactively with regulators on impurity concerns, and account for diverse payer expectations. Manufacturing decisions in this region are influenced by cost structures, skilled workforce availability, and the presence of specialty chemical suppliers for fluorinated intermediates, which can either ease or complicate scaling strategies depending on the specific locale.

Asia-Pacific plays a dual role as both a source of specialized chemical suppliers and a rapidly growing market for advanced therapeutics. Many sponsors rely on regional manufacturing partners for cost-effective synthesis of fluorinated precursors, but this dependence heightens the importance of supplier qualification and geopolitical risk assessment. Additionally, regulatory harmonization efforts across certain markets are improving the predictability of approval pathways, which can accelerate launch timelines when properly navigated.

Across all regions, competitive intensity and talent availability shape where companies choose to site R&D and production activities. Sponsors increasingly adopt hybrid footprints that balance cost, speed, and resilience, and regional strategy decisions must be informed by a clear understanding of local regulatory expectations, supply chain capacities, and clinical development ecosystems.

Profiles of leading companies, partnerships, and innovation pathways defining competitive positioning and R&D focus in fluorinated drug discovery

Leading companies in the fluorinated drugs ecosystem are defining competitive positions through a combination of platform capabilities, strategic partnerships, and targeted R&D investments. Organizations that have invested in advanced fluorination chemistries, high-throughput screening of fluorinated libraries, or proprietary process-intensification technologies are better positioned to accelerate lead optimization and to reduce the time between candidate selection and IND-enabling work. Partnerships between discovery-stage companies and specialty chemistry providers are also playing a pivotal role in bridging capability gaps and in de-risking scale-up of fluorinated intermediates.

Collaborative models extend beyond chemistry into co-development and licensing arrangements that enable sponsors to access complementary assets while sharing development risk. Alliances that integrate clinical development expertise with manufacturing capacity allow programs to maintain momentum even as synthetic complexity rises. In parallel, a subset of firms is differentiating through vertical integration, securing in-house capabilities for both discovery and GMP manufacturing to preserve control over critical supply chains and to protect proprietary process know-how.

Investor attention and corporate strategy are often guided by the ability to demonstrate translation from chemical innovation to clinical differentiation. Firms that can show a clear regulatory strategy for managing fluorine-related impurities, coupled with cost-effective manufacturing plans, tend to attract partnerships and favorable terms. Observationally, companies with focused clinical portfolios that leverage fluorination to address unmet needs or to enable novel delivery modes attract more concentrated development resources and strategic collaborations.

Taken together, these corporate behaviors indicate that success in this space depends on aligning chemical innovation with operational excellence and strategic partnerships that can bridge gaps in scale-up, regulatory navigation, and market entry.

Clear, prioritized, and actionable recommendations designed to help industry leaders optimize R&D investments, supply resilience, and regulatory engagement in fluorinated therapeutics

Industry leaders must adopt a set of prioritized, pragmatic actions to capture the scientific advantages of fluorination while controlling operational and regulatory risk. First, teams should institutionalize closer collaboration between medicinal chemistry, process development, and regulatory affairs to ensure that fluorination decisions made in discovery are informed by downstream manufacturing feasibility and impurity management. Early cross-functional alignment reduces rework and accelerates the transition from candidate selection to clinical batches.

Second, sponsors should diversify supplier relationships for critical fluorinated reagents and intermediates while concurrently qualifying secondary sources through technical transfer exercises. This dual approach preserves continuity even if geopolitical or tariff pressures shift the cost landscape. Parallel to supplier diversification, companies should invest in analytical method development and impurity profiling early in the program to forestall regulatory issues and to support robust comparability packages.

Third, R&D leaders should prioritize modular process development strategies that enable flexible scale-up. Adopting flow chemistry, telescoped sequences, and other intensified processes can reduce the number of purification steps and lower impurity burdens. These technical choices should be validated with manufacturing risk assessments that feed into contingency plans for clinical supply.

Finally, commercial and access teams must be engaged early to align evidence generation with payer and provider expectations. If fluorination enables differentiated clinical benefits-such as reduced dosing frequency or improved tolerability-the economic case should be articulated and supported by clinical and health-economic analyses. Implementing these recommendations will improve program robustness, enhance resilience to tariff and supply shocks, and increase the likelihood that scientific advantages produce tangible patient and commercial outcomes.

A transparent research methodology outlining data sources, validation approaches, expert consultations, and analytical frameworks used to evaluate drug trends

The research approach underpinning this analysis combines a structured review of peer-reviewed literature, primary expert consultation, and synthesis of regulatory guidance to deliver reproducible and defensible conclusions. Data collection began with targeted literature mapping to capture advances in fluorination chemistry, process intensification, and clinical applications, followed by a thematic assessment of publicly available regulatory documents and guidance relevant to halogenated compounds. This baseline was augmented by structured interviews with subject-matter experts in medicinal chemistry, process development, regulatory affairs, and supply chain management to validate assumptions and to surface practical challenges encountered during development and scale-up.

Analytical frameworks included qualitative risk assessments, scenario analysis for supply chain disruptions and tariff impacts, and cross-segmentation mapping to reveal where scientific attributes intersect with therapeutic and commercial imperatives. Validation steps involved triangulating interview insights with published case studies and regulatory precedents to ensure consistency and to minimize bias. Where appropriate, sensitivity checks were conducted to test the robustness of strategic recommendations under alternative operational conditions.

Transparency and reproducibility were maintained by documenting data sources, interview protocols, and the criteria used for evaluating technological readiness and regulatory risk. This methodological rigor supports confident application of the findings to decision-making and allows users to adapt the approach to their specific program needs or organizational contexts.

Conclusion synthesizing strategic implications, emerging risks, and opportunities for stakeholders active in fluorinated drug innovation and market entry

In conclusion, fluorinated drugs represent a strategic frontier where chemical innovation can materially enhance clinical profiles but also introduces operational and regulatory complexity that cannot be ignored. The interplay among synthetic accessibility, impurity control, supply chain resilience, and clinical differentiation determines whether the theoretical advantages of fluorination translate into real-world therapeutic and commercial success. Stakeholders must therefore adopt integrated strategies that bring together discovery science, process development, regulatory planning, and commercial alignment.

Emerging risks-such as changing tariff landscapes, supplier concentration, and evolving regulatory expectations-underscore the importance of proactive mitigation, including supplier diversification, early analytical development, and modular process design. At the same time, opportunities exist for players that can deliver differentiated clinical outcomes through judicious application of fluorination chemistry and that can articulate a clear value proposition to payers and providers.

For executives and program leads, the path forward involves making deliberate choices about where to invest, which partnerships to pursue, and how to structure development programs to balance scientific ambition with operational pragmatism. When these elements are aligned, fluorinated therapeutics can deliver meaningful advantages to patients and create durable competitive differentiation for sponsors.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fluorinated Drugs Market, by Drug Type

  • 8.1. Biologics
    • 8.1.1. Monoclonal Antibodies
    • 8.1.2. Nucleic Acids
    • 8.1.3. Recombinant Proteins
  • 8.2. Peptides
  • 8.3. Small Molecules

9. Fluorinated Drugs Market, by Therapeutic Area

  • 9.1. Autoimmune
  • 9.2. Cardiovascular
    • 9.2.1. Atherosclerosis
    • 9.2.2. Heart Failure
    • 9.2.3. Hypertension
  • 9.3. Central Nervous System
  • 9.4. Oncology
    • 9.4.1. Hematological
    • 9.4.2. Solid Tumor
  • 9.5. Respiratory
    • 9.5.1. Asthma
    • 9.5.2. Chronic Obstructive Pulmonary Disease

10. Fluorinated Drugs Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Injectable
  • 10.3. Oral
  • 10.4. Topical
  • 10.5. Transdermal

11. Fluorinated Drugs Market, by Development Stage

  • 11.1. Approved
  • 11.2. Phase I
  • 11.3. Phase II
  • 11.4. Phase III
  • 11.5. Preclinical

12. Fluorinated Drugs Market, by Compound Class

  • 12.1. Fluorinated Aliphatics
  • 12.2. Fluorinated Amino Acids
  • 12.3. Fluorinated Heterocycles
  • 12.4. Fluoroarenes

13. Fluorinated Drugs Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals
  • 13.4. Retail Pharmacies

14. Fluorinated Drugs Market, by Distribution Channel

  • 14.1. Direct Sales
  • 14.2. Distributors
  • 14.3. E-Commerce

15. Fluorinated Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Fluorinated Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Fluorinated Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Fluorinated Drugs Market

19. China Fluorinated Drugs Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. Amgen Inc.
  • 20.7. AstraZeneca PLC
  • 20.8. Cipla Limited
  • 20.9. Eli Lilly and Company
  • 20.10. F. Hoffmann-La Roche AG
  • 20.11. GSK plc
  • 20.12. Johnson & Johnson
  • 20.13. Merck & Co., Inc.
  • 20.14. Novartis AG
  • 20.15. Pfizer Inc.
  • 20.16. Sanofi S.A.
  • 20.17. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FLUORINATED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FLUORINATED DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FLUORINATED DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES FLUORINATED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA FLUORINATED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FLUORINATED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY NUCLEIC ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY NUCLEIC ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY NUCLEIC ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ATHEROSCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY APPROVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY APPROVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY APPROVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY FLUORINATED ALIPHATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY FLUORINATED ALIPHATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY FLUORINATED ALIPHATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY FLUORINATED AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY FLUORINATED AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY FLUORINATED AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY FLUORINATED HETEROCYCLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY FLUORINATED HETEROCYCLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY FLUORINATED HETEROCYCLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY FLUOROARENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY FLUOROARENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY FLUOROARENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY E-COMMERCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY E-COMMERCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS FLUORINATED DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA FLUORINATED DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. GCC FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. GCC FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 244. GCC FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 245. GCC FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. GCC FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 247. GCC FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. GCC FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. GCC FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. G7 FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. G7 FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. G7 FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 279. G7 FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 280. G7 FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 281. G7 FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. G7 FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 283. G7 FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. G7 FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 285. G7 FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. G7 FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. G7 FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. NATO FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. NATO FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. NATO FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 291. NATO FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 292. NATO FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 293. NATO FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. NATO FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 295. NATO FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. NATO FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 297. NATO FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. NATO FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. GLOBAL FLUORINATED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES FLUORINATED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA FLUORINATED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA FLUORINATED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA FLUORINATED DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA FLUORINATED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA FLUORINATED DRUGS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA FLUORINATED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA FLUORINATED DRUGS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA FLUORINATED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA FLUORINATED DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA FLUORINATED DRUGS MARKET SIZE, BY COMPOUND CLASS, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA FLUORINATED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA FLUORINATED DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)